发现一种基于的胺抑制剂,具有口服生物可用性和疗效
H D Kleinert1, S H Rosenberg, W R Baker
1Abbott Laboratories, Abbott Park, IL 60064.
研究人员开发了一种基于的雷宁抑制剂,A-72517,在动物模型中显著改善了口服生物利用性. 这一突破表明了口服类药物的潜力.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物发现 药物发现 药物发现
- 生物化学 生物化学
背景情况:
- 类宁抑制剂传统上表现为口服吸收不良和肝脏快速排泄,导致口服生物可用性低 (<2%).
- 这种局限性阻碍了针对高血压等疾病的有效口服基治疗方法的开发.
研究的目的:
- 为了研究一种基于的新型素抑制剂A-72517.的口服吸收和疗效,A-72517.
- 评估较大的分子在口服后完好无损的全身吸收的潜力.
主要方法:
- 开发A-72517,一种基于的宁抑制剂,分子质量为706达尔顿.
- 在多种动物物种 (子,老鼠,,狗) 中评估A-72517的口服生物可用性.
- 在狗口服后对剂量相关的生理效应 (血压,血蛋白活性,血管素II水平) 的评估.
主要成果:
- A-72517显著增强了口服生物可用性,从子的8%到狗的53%.
- 在狗中,口服A-72517导致血压和氨酸 - 血管新生素系统组件的剂量依赖性降低.
- 血中药物度的增加与观察到的生理效应相关.
结论:
- 具有大量分子质量的基分子可以有效地被完好无损地吸收到全身循环中.
- 这些发现支持A-72517和类似的基于的药物用于口服的治疗潜力.
- 这项研究克服了口服类药物开发中的一个关键挑战.
更多相关视频
04:28Utilizing an Orally Dissolving Strip for Pharmacological and Toxicological Studies: A Simple and Humane Alternative to Oral Gavage for Animals
Published on: March 23, 2016
08:15Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
Published on: June 6, 2025
相关概念视频
Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
